This application seeks support for an interdisciplinary postdoctoral research training program which is designed to prepare clinicians for a full-time career in cancer research and education. Support for nine postdoctoral research fellows is requested. This training grant which, for 21 of its 25 years, provided a broad training in cancer biology and therapy, is focused on the studies of genetic and epigenetic alterations in cancer with the ultimate goal to use these molecular changes, which are unique to cancer cells as new indicators for detection of cancer cells and specific targets for therapy. The primary purpose of this training grant is to train the physician-scientist in basic and translational cancer research. This training grant is offered as two-year or more training program and has been a major support vehicle to provide an intensive research experience for physician trainees. The majority of the trainees enter this program via the Cancer Center Medical Oncology Fellowship Program but spend all but the first clinical year (which is funded from other resources) in full-time laboratory research. Only the most qualified and outstanding applicants are selected for these few slots. The training faculty who serve as mentors for individual trainees in this program are acknowledged leaders in their field. Examples include, but are not limited to, Drs. Volgestein and Kinzler (genetic changes in progression of cancer), Baylin and Herman (role of methylation in progression of cancer), Isaacs and Sukumar (molecular biology of prostate and breast cancer) and Pardoll and Jaffee (novel approaches to cancer vaccines). In addition a close interaction between the faculty of this training program with other graduate and postgraduate training programs in basic science in the School of Medicine provides comprehensive exposure to basic aspects of cancer biology. As part of their training curriculum, trainees are required to complete two courses in the basic aspects of cancer biology and therapy, and actively participate in ongoing seminars, including a presentation of their research at Fellows Research Day. Mentors monitor the trainee's research progress while continuously emphasizing ethical and responsible conduct of research.
The primary purpose of this training grant is to train the physician-scientist in basic and translational cancer research. This training grant is focused on the studies of genetic and epigenetic alterations in cancer with the ultimate goal to use these molecular changes, which are unique to cancer cells as new indicators for detection of cancer cells and specific targets for therapy.
|Zeidner, Joshua F; Zahurak, Marianna; Rosner, Gary L et al. (2015) The evolution of treatment strategies for patients with chronic myeloid leukemia relapsing after allogeneic bone marrow transplant: can tyrosine kinase inhibitors replace donor lymphocyte infusions? Leuk Lymphoma 56:128-34|
|Schweizer, Michael T; Zhou, Xian C; Wang, Hao et al. (2014) The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer. Eur Urol 66:646-52|
|Paller, Channing J; Wissing, Michel D; Mendonca, Janet et al. (2014) Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer. Cancer Med 3:1322-35|
|Suzman, Daniel L; Eisenberger, Mario A (2014) Determining the optimal treatment for metastatic castration-resistant prostate cancer: age should not be a factor. Eur Urol 65:884-6|
|Martin, Lainie P; Sill, Michael; Shahin, Mark S et al. (2014) A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 132:526-30|
|Bettegowda, Chetan; Sausen, Mark; Leary, Rebecca J et al. (2014) Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 6:224ra24|
|Zeidner, Joshua F; Gladstone, Douglas E; Zahurak, Marianna et al. (2014) Granulocyte-macrophage colony stimulating factor (GM-CSF) enhances the clinical responses to interferon-? (IFN) in newly diagnosed chronic myeloid leukemia (CML). Leuk Res 38:886-90|
|Suzman, Daniel L; Antonarakis, Emmanuel S (2014) High-dose itraconazole as a noncastrating therapy for a patient with biochemically recurrent prostate cancer. Clin Genitourin Cancer 12:e51-3|
|Zeidan, Amer M; Forde, Patrick M; Symons, Heather et al. (2014) HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant 20:314-8|
|Paller, C J; Olatoye, D; Xie, S et al. (2014) The effect of the frequency and duration of PSA measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer. Prostate Cancer Prostatic Dis 17:28-33|
Showing the most recent 10 out of 96 publications